Functional characterization of the promoter for the mouse SPTLC2 gene, which encodes subunit 2 of serine palmitoyltransferase  by Linn, Stephen C. et al.
FEBS Letters 580 (2006) 6217–6223Functional characterization of the promoter for the mouse SPTLC2
gene, which encodes subunit 2 of serine palmitoyltransferase
Stephen C. Linna, Lindsay M. Andrasa, Hee-Sook Kimb, Jia Weia, M. Marek Nagiecc,
Robert C. Dicksonc, Alfred H. Merrill Jr.a,*
a School of Biology and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA
b Department of Food Science and Technology, Kyungsung University, Republic of Korea
c Department of Molecular and Cellular Biochemistry, University of Kentucky School of Medicine, Lexington, KY 40536, USA
Received 23 August 2006; revised 9 October 2006; accepted 9 October 2006
Available online 19 October 2006
Edited by Sandro SonninoAbstract A series of luciferase reporter constructs was pre-
pared from a 1035-bp fragment of mouse genomic DNA ﬂanking
the 5 0-coding sequence for the SPTLC2 subunit of serine palmi-
toyltransferase, the initial enzyme of de novo sphingolipid bio-
synthesis. The full-length DNA fragment promoted strong
reporter gene expression in NIH3T3 cells while deletion and
site-directed mutagenesis indicated that the proximal 335 bp
contain initiator and downstream promoter elements, two prox-
imal GC boxes that appear to stimulate transcription in a coop-
erative manner, and several additional elements whose activity
cannot be accounted for by known factor binding sites. These
ﬁndings provide insight into the control mechanisms for tran-
scription of mammalian SPTLC2.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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construct1. Introduction
Serine palmitoyltransferase (SPT) catalyzes the condensa-
tion of L-serine and a fatty acyl-CoA (in most cases, palmi-
toyl-CoA) as the ﬁrst unique reaction of sphingolipid
biosynthesis de novo [1,2]. SPT is known to be essential for
survival of cells in culture when the medium is depleted of
sphingolipids (which otherwise can be provided by lipopro-
teins) [3,4], embryonic development [5,6], and some functions
of adult cells since mutations in one of the two SPT subunits
(SPTLC1) results in type I human hereditary sensory neurop-
athy [7–9]. Surprisingly, little is known about the regulation of
SPT expression considering that intermediates of the pathway
are highly toxic [10] and sphingolipids perform important
membrane functions, including raft formation [11], traﬃcking
[12], and cell–cell and cell–matrix interaction [13], as well as
regulate cell proliferation, migration, survival and other cell
behaviors [14,15].Abbreviation: SPT, serine palmitoyltransferase
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doi:10.1016/j.febslet.2006.10.025Mammalian SPT is (minimally) a heterodimer of two pep-
tides encoded by the genes SPTLC1 and SPTLC2 (which cor-
respond to the LCB1 and LCB2 genes of yeast) [16–23]. While
most eukaryotic cells appear to possess the capacity for de
novo sphingolipid biosynthesis, SPTLC2 and SPTLC1 expres-
sion varies signiﬁcantly among mammalian tissues [19,20]. A
number of physical and biochemical agents have been shown
to elevate SPT mRNAs, including UVA or UVB radiation
[24,25], endotoxin [26,27], inﬂammatory cytokines [26,27], nic-
otinamide [28], and others [1,2]. Both SPT genes have been
mapped to speciﬁc loci in the mouse (SPTLC1 on chromosome
13 and SPTLC2 on chromosome 12) and human genomes
(SPTLC1 to 9q22.2, SPTLC2 to 14q24.3-q31), and reference
nucleotide sequences of the ﬂanking regions have been deter-
mined [29–31]. The promoter elements and trans-acting factors
that control SPTLC2 and SPTLC1 gene transcription, how-
ever, have not been identiﬁed.
Here, we report the cloning and the ﬁrst functional analysis
of the candidate promoter region upstream of the ATG trans-
lation start codon of mouse SPTLC2. The promoter region
lacks a recognizable TATA motif but contains three GC-
boxes, two of which appear to function cooperatively. Other
potential control elements include an initiator (Inr) and down-
stream promoter element (DPE), a nuclear factor Y (NF-Y)
recognition sequence, and several regions whose activity can-
not be accounted for by known transcription factor binding
sites.2. Materials and methods
2.1. Cell culture and reagents
NIH3T3 cells (ATCC, Rockville, MD) were grown in Dulbecco’s
Modiﬁed Eagle’s Medium (D-MEM) supplemented with 100 U peni-
cillin/ml, 100 lg streptomycin/ml, and 10% (v/v) fetal bovine serum
(HyClone, Logan, UT). Cells were maintained at 37 C in an atmo-
sphere containing 5% CO2, and were transfected between passages 5
and 20.
2.2. Mouse SPTLC2 genomic clones
Two independent clones containing portions of the mouse SPTLC2
locus were obtained by screening 5 · 105 plaques from a lambda
EMBL3 SP6/T7 genomic library (Clontech, Palo Alto, CA) with a
430 bp EcoRI–StyI restriction fragment derived from the 5 0 end of
the murine SPTLC2 cDNA described by Nagiec et al. (GenBank
accession number U27455) [23]. The clones produced distinct restric-
tion patterns, but nucleotide sequences including and adjacent to the
region represented in the cDNA probe were the same in both cases.blished by Elsevier B.V. All rights reserved.
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ﬂanking DNA were acquired from one clone by the automated dye-ter-
minator method (Southwest Scientiﬁc Resources, Albuquerque, NM).
Sequences spanning positions +87 through 955 bp relative to the ﬁrst
nucleotide of the RIKEN mouse SPTLC2 cDNA clones G431001J02
(accession number BB865461) and G370001N18 (accession number
BB851468) were ampliﬁed by polymerase chain reaction (PCR) from
the lambda EMBL3 clone and from Swiss 3T3 ﬁbroblast genomic
DNA. Sense and antisense-strand ampliﬁcation primers were 5 0-
TCCCCCGGGAACATAGAGGGTCACTCAG-3 0 and 5 0-GGGGT-
ACCAGCACCCGGCAGCAGGAC-3 0, respectively, and both in-
cluded 5 0 extensions containing restriction enzyme sites to facilitate
cloning. Products were inserted into the pT7Blue vector (Novagen,
Madison, WI) and recombinants were screened by restriction enzyme
analysis of the inserts. The nucleotide sequences of two candidate
clones were determined by the Emory University DNA Sequencing
Core Facility (Atlanta, GA). One clone spanned the entire target re-
gion with the exception of a 7 bp 3 0-terminal deletion, but contained
several 5 0 point mutations. The second was truncated by 159 bp at
its 3 0 end but was otherwise identical to the original genomic sequence.
The two clones therefore were recombined at a common BlpI restric-
tion site to produce a construct, designated pT7-SPT2pro, that con-
tained wild type sequence extending from 955 to +80.
2.3. Computer analysis of nucleotide sequences
Genomic sequences were analyzed for the presence of likely pro-
moter elements using the programs TSSG and TSSW (Softberry,
Inc., Mount Kisco, NY) and TFSEARCH (Parallel Application
TRC Laboratory, RWCP, Japan). Alignments of nucleotide sequences
were performed with the MegAlign program (DNASTAR, Inc., Mad-
ison, WI), using the Clustal W method. Slight adjustments to gaps
were made based on visual inspection of the data.
2.4. Construction of SPTLC2 promoter deletion mutants
The insert of plasmid pT7-SPT2pro was subcloned into the pGL2-
Basic reporter vector (Promega, Madison, WI) upstream of sequences
encoding ﬁreﬂy luciferase, and the resultant construct was designated
pGL2mSPT2pro955. Deletions of the SPTLC2 promoter terminating
at 897, 603, 571, 357, 230, and 34 were generated by restric-
tion enzyme digestion and recircularization of this plasmid. Additional
deletion mutants were produced by PCR ampliﬁcation of the desired
segment from pGL2mSPT2pro 955 and cloning of the product into
pGL2-Basic. Sense strand primers were 5 0-TCAACCCGGGCTAAT-
TGGCTGTTCCTTTCC-30 (335); 5 0-ATTATCCCGGGCTCCGCC-
TCCTTCTCAACC-30 (317); 5 0-ATTACCCGGGTCTCAACCTG-
GACCAGTAGG-3 0 (301); 5 0-ATTACCCGGGAAGCTCC ACCT-
ACGACCTGG-30 (276); 5 0-CTAGTTCCCGGGCTCCAATCAA-
TTGCTCAG-30 (253); 50-ATAACCCGGGTGGTCAATAGCCG-
ATAGACC-30 (127); and 5 0-ATAACCCGGGTTTCCGGTTT-
CGGAGAGGTG-30 (+2). The antisense strand primer for all reactions
was 50-TAATGGTACCGCGGCAGCAGGACAGG-30. Each primer
incorporated a 5 0 restriction enzyme site and 4-nucleotide extension to
facilitate cloning of the products, and nucleotide sequences of promoter
inserts were veriﬁed prior to use of constructs in transient expression
experiments.
2.5. PCR-directed mutagenesis
Site-speciﬁc mutations of GC box sequences at positions 51 and
109 and CCAAT box sequences at 248 and 332 were created by
a two-step PCR procedure [32]. Brieﬂy, overlapping DNA fragments
containing the desired mutations were generated in separate reactions
where the antisense primer of one reaction was partially complemen-
tary to the sense primer of the other. The two products were then com-
bined and used as templates for ampliﬁcation of the entire target
region. Nucleotide sequences of the ﬁnal products were veriﬁed and
restriction fragments containing mutations were substituted for the
corresponding wild type fragments in the appropriate luciferase repor-
ter constructs. Mutations were designed to alter nucleotides that are
highly conserved or invariant in consensus sequences listed in the
TRANSFAC database [33] while avoiding creation of potential bind-
ing sites for transcription factors. Nucleotide sequence changes
(in the sense strand) were: 5 0-GTGGCCCCGCCCTCG-30 to
5 0-GTGGAAGTTAACTCG-3 0 (antisense GC box at 51); 5 0-
TAGACCCCGCCCCAT-30 to 5 0- TAGACAGTTAACCAT-30(antisense GC box at 109); 5 0-GGGCTCCAATCAATT-3 0 to
5 0-GGGCTCGTTTCATTT-3 0 (sense CCAAT box at 248); and
5 0-CTCTAATTGGCTGTT-30 to 5 0-CTCTAAAACGCTGTT-30
(antisense CCAAT box at 332) (the underlined nucleotides were
the ones that were altered).
2.6. Transfection of reporter constructs and assay of luciferase activity
Reporter constructs were transfected into NIH3T3 cells using Super-
fect reagent (Qiagen, Valencia, CA). Cells were seeded 24 h prior to
transfection at a density of 1 · 105 per 35-mm well and were between
50% and 60% conﬂuent at the time of DNA addition. Each well con-
tained 10 ll of Superfect reagent and 2 lg of plasmid DNA in 0.7 ml of
D-MEM + 10% fetal bovine serum. Plasmid mixtures consisted of
0.4 pmol of SPTLC2 reporter construct, 0.05 pmol of pRL-TK (Pro-
mega), and pGEM7Zf(+) carrier (Promega) as required to bring to
total mass of DNA to 2 lg. The pRL-TK construct encodes Renilla
reniformis (sea pansy) luciferase under control of the herpes simplex
virus thymidine kinase promoter, and was included as an internal con-
trol for variations in the eﬃciency of DNA uptake. Transfection was
allowed to proceed for 3 h at 37 C, 5% CO2, after which cells were
washed twice with PBS and incubated with 2 ml of fresh growth med-
ium for 24 h. Monolayers were washed once with PBS and cells were
lysed by 15 min incubation with passive lysis buﬀer (Promega). Lysates
were subjected to a single round of freeze–thaw, centrifuged brieﬂy to
pellet cell debris, and assayed for ﬁreﬂy and Renilla luciferase activities
using the Promega Dual Luciferase system with a Zylux Model FB12
luminometer (Zylux Corp., Maryville, TN).3. Results
3.1. Cloning and characterization of the mouse SPTLC2
promoter region
Two independent clones complementary to a 5 0-terminal
murine SPTLC2 cDNA fragment were identiﬁed in screens
of a mouse lambda EMBL3 SP6/T7 genomic library. Partial
nucleotide sequence analysis conﬁrmed that both included
SPTLC2 sequences surrounding and upstream of the ATG
translation start codon. An 1100 bp segment of one clone,
beginning with the ﬁrst nucleotide of codon 18 and extending
upstream, was sequenced to completion and determined to be
identical in all but two positions to chromosome 12 data
reported by the Mouse Genome Sequencing Consortium
(GenBank accession number NT_039551). Although the site
of transcription initiation in the murine SPTLC2 gene has
not been determined directly, comparison of genomic and
cDNA sequence data suggests that the current mRNA refer-
ence sequence (accession number NM_011479) probably does
not include the actual cap site. BLASTN alignment of
SPTLC2 exon 1 ﬂanking sequences with the mouse EST data-
base showed that 26 of the 30 best matches (E 6 5 · 10105)
terminate between 9 and 36 bp further upstream. The most dis-
tal endpoint, corresponding to the ﬁrst nucleotide of the
cDNA inserts in RIKEN clones G431001J02 and
G370001N18, lies within a sequence that ﬁts the initiator
(Inr) element consensus and matches the expected initiating
nucleotide [34]. This position was therefore designated as +1
for purposes of characterizing the promoter.
The 5 0-ﬂanking sequences of the mouse SPTLC2 gene con-
tain potential binding sites for a number of transcription fac-
tors, including proteins involved in basal gene expression,
cell diﬀerentiation, and enhancer-mediated responses (Fig. 1).
The proximal region lacks an obvious TATA element and, in
general, is G/C-rich. Like many TATA-less promoters, the
SPTLC2 sequences contain a potential binding site (GC box)
for the Sp1 family of transcription factors upstream of the
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-301 AAGCCCTACCCCGGACCTGGATGCGGCCTCCAATCAGGTGCCAGGCCCTGGAGTCCCTCTAGAGAAGCCCCCTCTCCACCGGCGAGGCGCTTTGCTCTCG Human
-177 CTCTTAATTCGCCAGA-ATCAGCATGAGATCCGCCCCTCTCGCCTTTGGATTGGTCAATAGCC--------------------GATAGA-CCCCGCCCCA Mouse
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-101 TTTTCCCTTCG-CTGCGTGGCCTTGGCCGAGACCGGTCCTCTGCGGAGAGGGCCCCGCCCTC-TGTGAAGGCCCGCCCGGGAATTGGCGGCGGCGCTGCA Human
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(NF-Y)
GC
c-Ets
SRY
(AP-1)
Presumptive cap site
Inr (DPE)
Oct-1
Oct-1
GC
GC
NF-Y
(NF-Y)
NF-YC/EBPβ
Fig. 1. Nucleotide sequence of the mouse SPTLC2 promoter region. Murine genomic sequences are aligned with homologous sequences from human
chromosome 14 (GenBank accession number AF111168). Gaps have been introduced where necessary to maintain alignment and identical sequences
are shaded. Nucleotides are numbered relative to the presumptive transcription initiation site in the mouse gene (see text), and a sequence matching
the initiator (Inr) element consensus PyPyA+1N(T/A)PyPy is labeled. A downstream sequence that matches the downstream promoter element (DPE)
consensus at 4 of 5 positions is shown in parentheses. Labeled bars indicate the positions of potential transcription factor binding sites. Sites
containing deviations from conserved nucleotides in the consensus sequence are shown in parentheses; potential binding sites with diﬀerences in
nucleotides considered to be invariant, or nearly so, were ignored.
S.C. Linn et al. / FEBS Letters 580 (2006) 6217–6223 6219Inr element (position 51). There is also a ﬁve-nucleotide
motif beginning at +27 that is similar in both sequence and dis-
tance from the Inr to the downstream core promoter element
(DPE) required for eﬃcient transcription from certain non-
TATA promoters [35]. Comparison of mouse and human
nucleotide sequences suggests that the SPTLC2 promoter
may be highly conserved in mammals. Positions 1 through
955 of the mouse gene are 73% identical to the corresponding
human sequence, and a number of potential binding sites for
basal and regulatory transcription factors are common to
both. These include the GC box, Inr, and DPE motifs de-
scribed above as well as two additional GC boxes at positions
109 and 313, and CCAAT-containing elements at 24,
132, 251, and 335. Much of the sequence that is similar
or identical in the mouse and human promoters lacks close
matches to existing transcription factor consensus sequences,
and its apparent conservation suggests the possible existence
of novel regulatory elements in the SPTLC2 promoter.
3.2. Basal transcription from the SPTLC2 promoter is
dependent on DNA elements downstream of position 335
A 1035 bp fragment ofSPTLC2 genomic DNA containing 5 0
untranslated and upstream nucleotide sequences was sub-
cloned into the pGL2-Basic luciferase reporter vector and
transfected into NIH3T3 ﬁbroblasts (Fig. 2). Luciferase
expression from this plasmid was 46000-fold higher than
the background level produced by a pGL2-Basic negative con-
trol, demonstrating the presence of a functional promoter inthe insert. The approximate locations of basal transcription
control elements in the promoter were determined by progres-
sive deletion analysis of the parental pGL2mSPT2pro 955
construct. As shown in Fig. 2A, 5 0-truncation from position
955 bp to 357 bp did not signiﬁcantly alter reporter gene
expression. This observation was supported by experiments
with promoters terminating at 897, 603, and 571 bp,
which also had activities that were indistinguishable from the
955 bp reporter construct (data not shown). Signiﬁcant
decreases in luciferase expression were observed when the
promoter was truncated from 357 to 301, 301 to 230,
127 to 34, and 34 to +2 bp, indicating the presence of
functional elements in these regions. No statistically signiﬁcant
change in activity occurred when the promoter length was de-
creased from 230 to 127 bp. Although luciferase expression in
cells transfected with the +2 bp deletion mutant was less than
2% of the level obtained with the 955 bp construct, activity
was consistently above the background observed in cells con-
taining a promoterless vector, consistent with the presence of
minimal recognition sequences for the core transcription
machinery in the vicinity of the putative cap site.
A more detailed map of the distal promoter region was pro-
duced by analysis of a series of seven deletion mutants termi-
nating between positions 357 and 230 (Fig. 2B).
Truncation of the promoter to 335 bp, which eliminated a
potential binding site for the transcription factor C/EBPb,
did not signiﬁcantly alter luciferase expression relative to
the 357 bp control. Progressive decreases in activity were
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Fig. 2. Sequence elements required for basal transcription are located
within the ﬁrst 335 bp of the mouse SPTLC2 promoter region. (A)
Luciferase reporter constructs containing promoter segments extend-
ing from +80 to the indicated 5 0 endpoints were transfected into
NIH3T3 cells and luciferase activity was assayed after 24 h. Data were
normalized to the reporter activity of a cotransfected pRL-TK plasmid
and background luciferase activity determined by transfection of a
promoterless vector was subtracted. Activities are expressed relative to
the 955 bp promoter and results shown represent the means ± S.E.M.
of at least three independent experiments. Decreases in promoter
activity that are signiﬁcant relative to the prior construct in the
deletion series (single-factor Anova) are indicated by the appropriate P
value. (B) Promoter deletion mutants terminating between positions
230 and 357 were assayed as described above. Locations of
potential transcription factor binding sites in relationship to the
deletion endpoints are indicated. Activities are expressed relative to the
357 bp promoter and results shown represent the means ± S.E.M. of
at least nine independent experiments. Decreases in promoter activity
that are signiﬁcant relative to the prior construct in the deletion series
(single-factor Anova) are indicated by the appropriate P-value.
Promoter activity of the 317 bp mutant was signiﬁcantly diﬀerent
from the 357 bp control (P < 0.05) as well as from the 335 bp
mutant.
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Fig. 3. Two consensus GC boxes at positions 51 and 109 account
for basal SPTLC2 promoter activity in the 34 to 127 bp region. (A)
NIH3T3 cells were transfected with luciferase reporter constructs
containing the wild type 955 bp promoter or promoters containing
mutations in the 109 bp, 51 bp, or both GC-boxes. Control cells
were transfected with a 127 bp deletion mutant lacking the upstream
promoter domain and a 34 bp mutant in which both GC-boxes are
removed. Luciferase activity was assayed after 24 h and normalized to
the reporter activity of a cotransfected pRL-TK plasmid. Background
luciferase activity determined by transfection of a promoterless vector
was subtracted and all activities are expressed relative to the 955 bp
wild type (wt) promoter. Results shown represent the means ± S.E.M.
of three independent transfections. (B) Cells were transfected with a
127 bp promoter deletion mutant containing the wild type sequence
or the GC-box mutations described above. Control cells were
transfected with the 357 bp or 34 bp promoter construct. Lucifer-
ase activity was assayed after 24 h and normalized to the reporter
activity of a cotransfected pRL-TK plasmid. Background luciferase
activity determined by transfection of a promoterless vector was
subtracted and activities are expressed relative to the wild type
955 bp promoter. Results shown represent the means ± S.E.M. of
three independent transfections.
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276 to 253, and 253 to 230 bp, however. While some of
these deletions removed sequences that closely match known
consensus binding sites for transcription factors, no such mo-
tifs could be identiﬁed in the region between positions 301
and 253.
3.3. Two proximal GC boxes are functional components of the
basal SPTLC2 promoter
Truncation of the SPTLC2 promoter region from 127 to
34 bp resulted in a 10-fold decrease in reporter gene expres-
sion and removed only two sequences that closely match
known transcriptional control elements, a pair of GC boxes
(potential Sp1 binding sites) located at positions 51 and109. To investigate the role of these elements in basal pro-
moter activity, we prepared a series of reporter plasmids in
which one or both sites were mutated to alter the core consen-
sus sequence from 5 0-CCCGCC-3 0 to 5 0-AGTTAA-3 0. Muta-
tion of the 109 GC box reduced the activity of a 955 bp
promoter by 15%, while the eﬀect of mutating the 51 site
was somewhat greater, producing a 26% decrease in reporter
gene expression (Fig. 3A). When both sequences were mutated,
activity was reduced by 56%, an amount greater than the sum
of the individual eﬀects. These observations are consistent with
involvement of both GC boxes in promoting transcription of
the SPTLC2 gene, and suggest that direct or indirect coopera-
S.C. Linn et al. / FEBS Letters 580 (2006) 6217–6223 6221tivity may exist between proteins bound to the two sites. In the
context of a promoter segment terminating at position 127,
the 51 GC box mutation and the 109/51 double mutation
both reduced luciferase expression to a level equivalent to the
34 bp deletion mutant, demonstrating that the two GC boxes
can account for all basal promoter activity associated with the
127 to 51 bp region (Fig. 3B). Surprisingly, cells transfected
with a construct in which only the 109 site was mutated
exhibited no luciferase expression above the background pro-
duced by a promoterless control plasmid. Nucleotide sequence
analysis of the promoter and luciferase coding region of the
127/GC109 plasmid revealed no secondary mutations, and
reporter gene expression from a co-transfected internal stan-
dard construct was normal, suggesting that cell toxicity or
some other nonspeciﬁc factor was not responsible for the lack
of enzyme activity. It is possible that alteration or absence of
the 51 GC box compensated in some way for a highly dele-
terious eﬀect of the 109 mutation, although the mechanism
by which this would occur is unclear and similar behavior
was not observed when the 127 to 955 bp sequence was
present.
3.4. Distal CCAAT boxes in the SPTLC2 promoter region
may be targets for negative regulatory factors
Two of the upstream deletion mutations that reduced
SPTLC2 promoter activity eliminated copies of the CCAAT
motif, one located in the sense DNA strand at 248 bp and
the other in the antisense strand at 332 bp. Both CCAAT
boxes are components of larger sequence elements similar to
the consensus binding site for nuclear factor Y (NF-Y), a ubiq-
uitous transcription factor that is known to interact with Sp1
[36]. To test if these elements are involved in basal expression0
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Fig. 4. Mutation of CCAAT sites at 332 and 248 increases
SPTLC2 promoter activity. NIH3T3 cells were transfected with
luciferase reporter constructs containing the wild type (wt) 955 bp
promoter or substitution mutations in the 248 bp sense strand or
332 bp antisense strand CCAAT sequences. Luciferase reporter
activity was assayed after 24 h and normalized to the activity of a
cotransfected pRL-TK plasmid. Background luciferase activity deter-
mined by transfection of a promoterless vector was subtracted from all
values. Activities are expressed relative to the wild type 955 bp
promoter and results shown represent the means ± S.E.M. of three
independent transfections. Reporter gene expression from both
mutants was signiﬁcantly greater than from the wild type control
(P> 0.001 in single-factor Anova) but the mutants were not signif-
icantly diﬀerent from one another (P > 0.10).of SPTLC2, derivatives of the pGL2mSPT2pro 955 reporter
construct were prepared with changes in the essentially invari-
ant central nucleotides of the CCAAT motif (5 0-CCAA-
T-3 0 ﬁ 5 0-CGTTT-3 0). In contrast to results obtained in
the deletion experiments, directed mutation of either CCAAT
motif produced a 30–40% increase in reporter gene expression
(Fig. 4), which suggests that these sequences do not contribute
to basal SPTLC2 promoter activity but might act as binding
sites for negative transcriptional regulators. It also raises the
possibility that the 335 to 318 bp and 253 to 231 bp
regions contain novel regulatory elements that account for
the decrease in promoter activity observed in these mutants.4. Discussion
This study provides the ﬁrst insights into mechanisms
that control basal expression of SPT. A ‘minimal’ luciferase
reporter construct containing SPTLC2 genomic sequences
extending from +2 to +80 bp relative to the presumptive tran-
scription initiation site exhibited low but consistently measur-
able levels of gene expression above vector background in
NIH3T3 cells. While the precise location of the SPTLC2 cap
site has not been determined experimentally, comparison of
mouse genomic and EST sequences clearly indicates that the
region included in this construct is transcribed in a variety of
tissues. Thus, sequences surrounding and immediately down-
stream of the initiation site are likely to contain elements that
participate in recruiting TBP-associated factors (TAFs) or
other components of the core transcription machinery. Consis-
tent with this view, the mouse and human SPTLC2 promoter
regions include conserved matches to the initiator (Inr) consen-
sus PyPyA+1N(T/A)PyPy and a sequence 27 bp downstream
that is similar to the downstream promoter element (DPE)
consensus (A/G)G(A/T)(C/T)(G/A/C) [35]. A functional Inr
and one or more downstream elements, such as the DPE or
DCE (downstream core element) [37], are typically required
for transcription of genes like SPTLC2 that lack a TATA
box, and it has been suggested that the pattern of these core
elements may dictate a ‘preference’ for regulation by speciﬁc
enhancers and activators [38]. The precise role of such
sequences in basal and regulated SPTLC2 transcription,
however, remains to be determined.
The results of our deletion analyses indicate that the
SPTLC2 promoter has an upstream boundary at or near
335 bp and consists of proximal and distal functional do-
mains separated by approximately 100 nucleotides with no
obvious role in promoter activity. The proximal domain ex-
tends to position 127 and includes the putative Inr, a segment
between positions +2 and 34 that contains an inverted
CCAAT box, and a pair of GC boxes that are likely binding
sites for members of the Sp family of transcription factors
[39]. These GC boxes (or more properly the activators bound
to them) appear to function cooperatively, based on the obser-
vation that mutation of both sites in the context of a 955 bp
promoter had a more pronounced eﬀect than the sum of the
individual mutations (56% decrease vs. 15% and 26% de-
creases). Proteins bound to the GC boxes could also interact
with transcription factors bound further upstream. This view
is supported by our ﬁnding that the apparent synergism be-
tween the two GC elements disappeared when sequences
6222 S.C. Linn et al. / FEBS Letters 580 (2006) 6217–6223upstream of position 127 were absent. The pronounced de-
crease in reporter activity (P 90%) that occurred upon muta-
tion of these sites in the 127 bp promoter, however,
indicates that Sp family activators or other proteins bound to
the proximal GC boxes play a role in basal SPTLC2 transcrip-
tion that extends beyond mediating the eﬀects of other factors.
The upstream portion of the SPTLC2 promoter, consisting
of sequences between positions 230 and 335, contains at
least four functional DNA elements. One of these, located be-
tween 301 and 317 bp, maps almost precisely to a GC box
and is a possible binding site for Sp1 or another Sp-family pro-
tein. The forward and inverted CCAAT motifs at 248 and
332 bp, respectively, are potential targets of the transcription
factor NF-Y (also known as CCAAT-binding factor or CBF),
although they are located further upstream than the position at
which NF-Y typically acts [40]. The loss of promoter activity
observed in 5 0 deletion mutations that eliminate the
CCAAT-containing DNA segments is consistent with the
binding of an activator; however, site-directed mutagenesis
of the CCAAT sequences suggested that they are targets of
transcriptional repressors. One explanation for these appar-
ently conﬂicting observations is that sequence elements ﬂank-
ing the CCAAT motifs may act as transcription factor
binding sites or, alternatively, that the CCAAT elements could
be recognized by two or more regulatory proteins with oppos-
ing activities, whose binding is diﬀerentially inﬂuenced by up-
stream sequences that are present in the site-directed mutants
and absent in the deletions. Interestingly, NF-Y is known to
participate in both transcriptional activation and repression,
and to regulate genes involved in cell cycle progression [41].
Given the demonstrated abilities of sphingolipid intermediates
to inﬂuence cell proliferation and apoptosis, it is tempting to
speculate that SPT gene transcription might be subject to cell
cycle-dependent control by NF-Y or some other factor. The
existence of such a relationship remains to be investigated,
however. The fourth upstream element of the SPTLC2 pro-
moter lies between positions 253 and 276, a region that
does not contain obvious matches to existing transcription fac-
tor consensus binding sites. This raises the possibility that
basal transcription of the SPTLC2 gene is dependent on one
or more novel protein factors, or that a known factor may
bind to a previously unrecognized sequence motif. Further
mutational analysis of the promoter in concert with protein
binding studies will be required to resolve these questions.
Although cDNA and genomic clones encoding the major en-
zymes of sphingolipid metabolism have been isolated from a
variety of species, we are aware of only one previous study that
addresses the functional organization of any of the correspond-
ing promoters. Kolaczkowski et al. [42] demonstrated that
pleiotropic drug-resistance (Pdr) pathway activation of the pro-
moter for LAC1, one of two Saccharomyces cerevisiae genes re-
quired for dihydroceramide synthase activity, is dependent on
binding of the zinc cluster transcription factor Pdr1p or Pdr3p
to a pleiotropic drug resistance element (PDRE) [42]. The tran-
scription factors Cb1p and Rox1p were implicated in negative
regulation of the LAC1 promoter, while the SPTLC2 ortholog
LCB2 was found to contain a functional PDRE in its promoter
region and was induced via the Pdr regulatory pathway. Exis-
tence of common transcriptional activators for dihydrocera-
mide synthase and serine palmitoyltransferase would be
consistent with a coordinate mechanism of gene regulation,
but the broader signiﬁcance of these ﬁndings is diﬃcult to as-sess. First, the LCB2 and LAC1 promoter regions of S. cerevi-
siae diﬀer signiﬁcantly from those of homologous mammalian
genes, and orthologs of Pdr1p/Pdr3p, Cbf1p, and Rox1p have
been identiﬁed primarily, if not exclusively, in fungi. Second,
the number of genes involved in mammalian dihydroceramide
synthesis appears to be greater than in yeast, suggesting that
the corresponding transcriptional regulatory pathways are
likely to be more complex [43,44].
The data reported here provide a foundation for studying
expression of the SPTLC2 gene in metazoan species, including
signal transduction pathways that alter serine palmitoyltrans-
ferase mRNA levels and the possibility of coordinate regula-
tion with other genes involved in sphingolipid metabolism.
Perhaps signiﬁcantly, alignment of mouse and human
SPTLC1 cDNA sequences with their genomic counterparts
indicates that the 5 0 ﬂanking regions lack an obvious TATA
motif and contain several GC-boxes. Further investigation will
be required to determine if this structural similarity between
the two SPT promoter regions reﬂects shared mechanisms of
transcriptional control, and if expression of other sphingolipid
metabolic genes is regulated by common subsets of nucleotide
sequences and protein factors.
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